Northwire Canada EditionFriday, July 31, 2026
Sign inSubscribe
Northwire
⌕
NMI 0.195 +0.0% TKO 9.87 +4.4% ELD 45.89 +2.2% DG 0.045 +12.5% TNGD 6.33 +3.4% DPM 52.30 +6.1% EPL 0.180 +2.9% NTH 0.160 +3.2% GGM 0.035 +0.0% ITR 3.01 +4.9% CS 13.25 +3.5% EMO 0.325 +1.6% CAN 0.050 −9.1% MOON 7.40 +3.4% FG 0.035 +0.0% SBMI 0.125 +0.0% NMI 0.195 +0.0% TKO 9.87 +4.4% ELD 45.89 +2.2% DG 0.045 +12.5% TNGD 6.33 +3.4% DPM 52.30 +6.1% EPL 0.180 +2.9% NTH 0.160 +3.2% GGM 0.035 +0.0% ITR 3.01 +4.9% CS 13.25 +3.5% EMO 0.325 +1.6% CAN 0.050 −9.1% MOON 7.40 +3.4% FG 0.035 +0.0% SBMI 0.125 +0.0%
M&A / Property

Aurora Announces Distribution Partnership with Leafio Australia

By The Northwire Desk — AI Analysis Dec 02, 2025 · 07:00 ACB · 6.37 AURORA CANNABIS INC. J
ACB · Price

Executive Summary

  • Aurora Cannabis’ Australian subsidiary, MedReleaf Australia, entered a distribution partnership with Leafio (the wholesale arm of Montu Australia) to expand patient access to its medical cannabis products across Australia.
  • The agreement gives Leafio access to Aurora’s portfolio—including MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed brands—and leverages Leafio’s network of over 4,000 pharmacies nationwide.
  • The partnership is positioned as a strategic move to enhance market penetration, support clinician education, and drive growth in the Australian medical cannabis market.

Key Details

  • Parties: Aurora Cannabis Inc. (via wholly‑owned subsidiary MedReleaf Australia) and Leafio (Montu Australia’s wholesale distribution arm).
  • Scope of Distribution: Leafio will act as wholesaler for Aurora’s premium medical cannabis products across its nationwide supply chain serving >4,000 pharmacies.
  • Brands Included: MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., IndiMed.
  • Strategic Rationale: Improves patient access to consistent, high‑quality medical cannabis; provides educational resources for healthcare professionals; supports research and product innovation in the region.
  • Quotes:
  • Stanley Sack, Interim Managing Director, MedReleaf Australia – highlighted combined TGA‑GMP certification and Leafio’s sector knowledge as ideal for market growth.
  • Nicole Le Maistre, General Manager, Leafio – emphasized expanded patient reach, trusted medical channels, and benefits to the industry.
  • Geographic Focus: Australia (nationwide distribution through pharmacy network).
  • Forward‑Looking Statements: Include expectations of continued growth in the Australian market, enhanced research, product innovation, and improved patient outcomes.

Notable Quotes

  • “We are excited to join forces with Leafio to improve access to consistent, high‑quality medical cannabis for Australian patients.” – Stanley Sack, Interim Managing Director, MedReleaf Australia
  • “Together, Leafio and Aurora can reach more Australian patients through trusted medical channels, bolstering access to world‑class products and expertise.” – Nicole Le Maistre, General Manager, Leafio
Read the original news release →

More from AURORA CANNABIS INC. J

Jun 11, 2026 · 07:05

Record FY2026 revenue masks structural margin contraction and explicit FY2027 guide-cut; cash-rich but capital allocation remains dilutive.

Earnings May 14, 2026 · 08:45

Aurora Cannabis Secures IP Rights Amidst Sector Consolidation and Price Stabilization

M&A / Property May 14, 2026 · 06:54

Aurora Secures IP Moat Amidst Dilution Concerns and Cash Burn

M&A / Property Apr 28, 2026 · 15:57

Aurora Cannabis Expands Global Medical Portfolio Amidst Dilution Concerns and Profitability Push

Production / Operations Apr 28, 2026 · 06:53

Product Expansion Validates EU Capacity Play, But Dilution Risk Looms Over Cash Burn

Production / Operations Apr 15, 2026 · 07:05

Aurora Cannabis Acquires EU GMP Capacity Amidst Stock Decline

M&A / Property